Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says

[ad_1] Research at Biogen Source: Biogen Alzheimer’s patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai shows.  The Japanese drugmaker and its partner Biogen last week released an additional analysis of clinical trials of the monoclonal antibody drug, which is also known as lecanemab. Alzheimer’s disease continued to progress at a slower…

Read More

Pfizer RSV vaccine for older adults should be monitored for nervous system condition Guillain-Barre, scientists say

[ad_1] A health worker prepares a flu vaccine shot before administering it to a local resident in Los Angeles, the United States, on Dec. 17, 2022. Xinhua News Agency | Getty Images People who receive Pfizer‘s RSV vaccine for older adults should be monitored for Guillain-Barre syndrome, after two people developed the nervous system disorder…

Read More